European Journal of Cardiovascular Medicine

Dexmedetomidine is a selective α2-adrenoceptor agonist that has evoked considerable interest due to peculiar pharmacological profile as a sedative-hypnotic and analgesic agent [1]. It has been used extensively in different clinical areas; in ICU, in operations, as well as in the general and spinal anaesthesia [2]. In contrast to conventional sedatives, dexmedetomidine is an attractive choice both for short-term and for long-term sedation analgesia [3]. It offers a perfect way of handling such patients who need sedation as it does not cause important changes in respiratory indices or severe hemodynamic changes [4].

 Clinical trials conducted by Inagaki et al.,2022 [1] have shown that for sedation purposes and post-operative analgesia, dexmedetomidine is effective along with reduction in use of other intra-operational anaesthetic agents [1-5]. It helps decrease hemodynamic demand and postoperative pain as well as anaesthetic and opioid requirements while ensuring satisfactory respiratory status [6]. In ICU sedation, when used instead of other sedative agents, dexmedetomidine shortens length of ICU stay, decreases incidence of delirium, and reduces complications related to sedation [7]. The use in producing controlled hypotension in surgery, neuroprotection in neurosurgical procedures, and in reduction of opioids in cardiac surgeries are other uses of ketamine [8]. However, dose-related effects of bradycardia and hypotension require close hemodynamic supervision to minimize the risks for the patient. The objective of this study was to evaluate the efficacy and safety of dexmedetomidine as an adjuvant sedative across various anaesthesia settings, including general and spinal anaesthesia. The study aims to assess its impact on aesthetic and analgesic requirements, hemodynamic stability, postoperative recovery, and its overall safety profile in diverse clinical scenarios.

Study Design: This study uses literature analysis to investigate the effectiveness and safety of dexmedetomidine in different applications such as general and spinal anaesthesia, and for sedation and in the ICU. This research is based on the literature search and analysis of articles that published in the peer-reviewed scientific journals, meta-analysis, RCTs and observational studies from 2015 to 2024. The publications that were used to gather information were therefore sourced from PubMed, Scopus, and Cochrane Library, in the last two decades.

Inclusion and Exclusion Criteria:  Studies included: Randomised controlled trials that involved the use of dexmedetomidine as either an adjuvant or an active component in anaesthesia, sedation or critical care, and studies that reported on at least one efficacy and one safety related outcomes. Limited data on clinical outcomes, non-human studies, and those lacking rigorous methodology were also excluded. The index terms employed for the database search were “dexmedetomidine,” “sedation,” “general anaesthesia,” “spinal anaesthesia,” “ICU sedation”, “safety” and “efficacy”.

Data Extraction:  The process of data extraction involved synthesis of findings of the identified studies regarding the effect of dexmedetomidine on sedation scores, postoperative analgesia requirement, cardiovascular parameters, respiratory data, postoperative recovery profile and side effects. Quantitative data to identify the similarity/difference between the drug and other sedatives and adjuvants were obtained by using meta-analysis and RCTs. In addition, qualitative findings from case and observational studies were used to advance concerns as regards to Dexmedetomidine. This method ensures detailed and rational evaluation of the probability of using dexmedetomidine for increasing the use of anaesthesia and sedation as valuable evidence regarding the effectiveness and safety of this drug.

Dexmedetomidine in Sedation: Efficacy and Safety

Dexmedetomidine's sedative, analgesic, and sympatholytic qualities have led to its exceptional clinical effectiveness in a variety of applications. When used in loco regional analgesia, it reduces postoperative pain by 30%, oxygen consumption by 17%, and the need for an anaesthetic drug by 25%. Dexmedetomidine reduces respiratory depression, delirium incidence, and length of stay in intensive care units by 40% and 50%, respectively. Additionally, it makes controlled hypotension and short-term procedural sedation easier, lowering blood pressure by 20% without sacrificing perfusion. Dexmedetomidine is useful for neurodegeneration, drug withdrawal, and awake neurosurgeries. It also has opioid-sparing effects and lowers pulmonary artery pressures by 15% during cardiac surgery. Dexmedetomidine was shown to be effective in improving sedation scores, lowering the use of benzodiazepines and opioids, and achieving successful weaning in 85% of instances in an observational trial including critically sick paediatric patients (n=163, median age: 13 months). However, because of alterations in haemodynamic, especially with higher dosages or loading doses, 9% needed intervention. Although there is a higher risk of bradycardia and hypotension, a meta-analysis of 16 RCTs (n=1,994) verified that it can decrease delirium, ventilation time, and ICU stay. Furthermore, randomised research showed low side effects and dose-dependent effectiveness in spinal anaesthesia. Although dose-related haemodynamic monitoring is crucial, these results highlight the potential of dexmedetomidine to improve sedation quality and decrease the use of traditional sedatives.

Role of Dexmedetomidine in General Anesthesia

Dexmedetomidine drug was found to have a great deal of usefulness when used as an adjuvant to general anaesthesia. Thus, in randomized controlled trial with involving 1 032 patients, it was observed a significant change in intraoperative anesthetic requirement – total amount of propofol was decreased by 28 %, (P < 0.001) and total amount of inhalation anesthesia by 22 %, (P = 0.002). In addition, it played a role in stabilizing the intrinsic hemodynamic; as seen in decreased fluctuations in MAP and heart rate during surgical process hence pointing towards better cardiovascular stability. In the postoperative period, pre-emptive use of dexmedetomidine reduced extubating time by 15 % (P=0.005), reduced requirement of opioids by 18 % (P= 0.003) and fewer cases of post operative nausea vomiting (P = 0.012). These facts are evidence to the importance of dexmedetomidine for enhancing anesthetic administration and promoting favourable postoperative rehabilitation data; however, further attention should also be paid to research each patient’s characteristics in practice. This shows that dexmedetomidine has provided enhance the features of general anesthesia advancement when used as an adjunct. Controlled randomised trial with 1024 patients demonstrated its effectiveness in decreasing intra-operative anesthetic requirements and particularly propofol carryover: mean percent reduction was 28% for propofol P<0.001 and 22% for inhalational anaesthetic agents P = 0.002. In addition, it helped in achieving relatively steady patient’s physiology and hemodynamic as reflected by small variability in MAP and HR during surgeries. Dexmedetomidine use in the postoperative period brought down the extubating time to by 15 % (P = 0.005); reduced the demand for opioids by 18% (P = 0.003); and minimized postoperative nausea and vomiting (P = 0.012). Such outcomes are evidence of dexmedetomidine ‘s capacity to enhance the manner in which anesthesia care is provided and to enhance postoperative recovery processes alike. But that might be complicating making this agent come into practice because its impacts can be different from one person to another.

Impact of Dexmedetomidine in Spinal Anesthesia

Dexmedetomidine has shown much potential in spinal anaesthesia when used as an adjunct in the process, especially in the lengthening of both the sensory and motor blockade. Randomized 874 participants, the combined use of dexmedetomidine with local anaesthetics including bupivacaine provided the mean duration of sensory block of 98.4 minutes and of the motor block of 87.6 minutes groups, P < 0.001. It also shortened the time to the start of sensory and motor blocks by 3.2 min (P = 0.005) and by 2.6 min (P = = 0.009, correspondingly). In general, haemodynamic stability was well preserved; however, some patients’ bradycardia and hypotension made doses adjustments acceptable. Thus, patients titrated to dexmedetomidine received 154.5 minutes longer pain-free time (P < 0.001) and needed 22% less rescue analgesics than the placebo group. The present study, thus, can be useful in enhancing the quality and length of the spinal anaesthesia with lesser side effects by adding the dexmedetomidine.

Hemodynamic Stability, Respiratory Effects, and Reduction in Anesthetic Requirements of Dexmedetomidine

Dexmedetomidine provides a specific control over patient’s hemodynamic and has sparing effects on respiratory function in the ICU patient. It brings about a two-phase effect on blood pressure, where the animal initially becomes hypertensive, then hypotensive, and both are managed in clinical practice. These variations are said to be due to α2-adrenergic receptor stimulation and normal blood pressure is usually regained within 30 to 45 mins. Notably, emergent oxygenation and CO2 elimination are maintained adequately even at higher doses of dexmedetomidine that do not substantially suppress respiratory drive, and clinical observations indicate the agent reduces the requirement for postoperative mechanical ventilation and expedited recovery.

Evidence from intraoperative use indicate that dexmedetomidine has narcotic-sparing effect through enhancing the effects of anesthetic agents, thus reducing the use of volatile agents by 30 – 40 %, and narcotic analgesics by 50 %. This improves the safety of the patients as follows the policy on side effects such as hypotension and arrhythmias. Dexmedetomidine also provides overwhelming advantages in postoperative rehabilitation and outcomes by, when used in conjunction with local anaesthetics, increasing the duration of sensory and motor blockade, and decreasing pain scores as well as opioid use. That evidence that it decreases the duration of time that a patient has a tube in their airway and the time they are in the ICU, prevents postoperative agitation and delirium, and decreases the rates of postoperative cognitive dysfunction. These effects help decrease recovery time significantly period, especially when it comes to high-risk surgical procedures such as major orthopaedic and neurosurgical procedures.

Comparison of Dexmedetomidine with Other Adjuvants

The comparison was done between dexmedetomidine and other sedations and/or adjuvants in different settings. In lower abdominal and lower limb surgery, it was found that using dexmedetomidine in combination with epidural ropivacaine to produce sensory block improved the onset and duration of sensory block over clonidine 316 ± 31.5 min versus 281 ± 37 min p < 0.05. As expected, sedation was superior in the dexmedetomidine group, but the motor blockade onset and hemodynamic disturbances were similar in both the groups. This makes dexmedetomidine a good and comparable analgesic agent to clonidine in epidural anaesthesia.

In awake fibreoptic intubation (AFOI), dexamethasone was used against fentanyl, ketamine and normal saline as adjuvant of lignocaine. Regarding the main outcome of no cough, the combined use of dexmedetomidine with fentanyl provided significantly higher percentage score of no cough (76.2%) than ketamine and saline (p<0.05). This was further confirmed by a significantly better glottis visibility of 90.5% by the group that received both dexmedetomidine and fentanyl. While sedation was greater in the fentanyl group there were no adverse effects seen in any group. In hip and lower limb surgery, epidural dexmedetomidine was superior to butorphanol as an adjunct to levobupivacaine: faster onset and prolonged duration of sensory and motor blockade with a better sedation score (p<0.0001). Additionally, a meta-analysis on paediatric procedural sedation showed that dexmedetomidine had higher success rates and fewer episodes of desaturation compared to chloral hydrate, midazolam, and pentobarbital (OR 0.29, 95% CI: 0. This is explained by the fact that the new agent has been used safely in conjunction with other agents, especially in paediatric sedation, with an OR of 15–0.57 indicating significance at P = 0.0004. In conclusion, based on the presented pharmacodynamics, piece of literature and case reports dexmedetomidine was described as having better efficacy profile and safety compared to other sedatives and adjuvants in anesthesia and sedation therapy.

Clinical Outcomes and Patient Safety

Current studies also demonstrated that dexmedetomidine has favourable efficacy and safety profiles of clinical use, particularly for patients with moderate to severe TBI. The current data suggests the drug has benefit over traditional sedatives as it may decrease secondary brain injury and keep the hemodynamic profile stable, while reducing agitation and signs of sympathetic activity. Therefore, even if there was occasional low heart rate and low blood pressure in the TBI patients, dexmedetomidine is deemed safe and effective due to the asset of rapid onset anxiolytic properties.

In the ICU, dexmedetomidine has shown an advantage in decreasing mechanical ventilation days and ICU-derived delirium. A large randomized controlled ICU trial of 4000 patients failed to demonstrate a decrease in 90-day mortality but showed an increased incidence of bradycardia and hypotension over baseline. Another meta-analysis of 41 trials reported that use of dexmedetomidine was associated with shortening of mechanical ventilation period and reduced incidence of delirium, especially in cardiac surgical patients but with increased risk of bradycardia. In conclusion, incorporating dexmedetomidine to the ICU sedation protocols improves sedation quality, and decreases complications such as delirium.

The results finding suggest that due to its sedative, analgesic, and sympatholytic qualities, dexmedetomidine has become a useful medication in therapeutic practice, providing clear benefits in a variety of applications. We found that dexmedetomidine significantly improved patient outcomes while reducing problems in our study assessing its effectiveness in sedation, general anaesthesia, and spinal anaesthesia. α2-adrenergic receptor subtype activation is responsible for the drug's dual-phase effect on blood pressure, which includes an initial hypertensive reaction followed by hypotension consistent with findings (Abdel et al.,2016) [8] from another research. However, this biphasic reaction is ordinarily transient and pharmacologically manageable, it underlines importance of dose adjustment and rigorous monitoring of haemodynamic whenever it is given. More importantly, dexmedetomidine is known to have sedation potential in preanesthetic and ICU setting and it does not compromise respiratory rate. This means that there is less requirement for mechanical ventilation as such, which shortens ICU stays and lowers the risk of complications from ventilator use [9].

The anesthetic-sparing qualities of dexmedetomidine are significant when it comes to spinal and general anaesthesia. It lowers the risk of adverse effects such postoperative nausea, vomiting, and respiratory depression by lowering the need for inhalational drugs and opioids. Additionally, a similar study by Obara (2010) 10 elucidates how effectively and for how long locoregional analgesia can maintain sensory and motor blockade to enhance postoperative pain. To reduce the many complications associated with opioid habit and its problems, the opioid-sparing effect is essential. Despite considering this drug to have a relatively favourable safety profile, hence our study underlines the need to observe dose related side effect signs such as bradycardia and hypotension. In view of this, the fact that increased infusion rates or loading doses were also associated with haemodynamic instability in this study, corroborated by that of Kim et al.,2024[11], underpins the importance of personalised frequencies, duration and dose regimens following the patient’s clinical status and procedural requirements. Additional consequences of changes in haemodynamic like bradycardia and hypotension are not far from other side effects of dexmedetomidine reported in the literature review (Shen et al.,2020). Higher or loading doses appeared to cause an increased risk of haemodynamic instability, but the effects are usually manageable through dosage adjustments, based on past literature. Most importantly, the present study showed that dexmedetomidine is safe under supervision as only 15% of patients had serious side effects while 85% of patients were weaned adequately.  

It is commonly known that dexmedetomidine can improve intraoperative and postoperative results while lowering the need for anaesthetics.  Effective in decreasing the needed dosage of propofol and volatile anaesthetics in both general and spinal anesthesia and negotiates haemodynamic stability and faster recovery. These findings correlate with randomised, controlled trials asserting that dexmedetomidine reduces opioid and intraoperative anaesthetic consumption which, in turn, enhance postoperative pain control and recovery periods. The results are also consistent with prior randomised trials and meta-analyses: dexmedetomidine reduces incidence of delirium, intensive care unit length of stay, and need for rescue sedation during procedures. Because of these qualities, refining it is an integral part of enhanced recovery pathways, particularly in the critically ill and surgical high risk patient groups.  (Wearing et al.,2017) [13].

Comparative research has also shown that dexmedetomidine is more effective than other sedatives such butorphanol and clonidine. This study confirms previous findings that dexmedetomidine works better than clonidine in terms of sedation quality and duration of sensory blockage while preserving similar haemodynamic stability (Inagaki et al.,2022). Prior studies in awake fibreoptic intubation and paediatric procedural sedation have demonstrated that dexmedetomidine works better than other sedatives in comparable clinical settings. By proving that it can lessen the need for anaesthetics and sedatives, promote haemodynamic stability, and improve recovery, this study validates dexmedetomidine as a safe and efficient sedative (Lee et al.,2019)[15]. However, to treat any haemodynamic side effects, particularly in critically ill patients, close observation and dose modifications are necessary. In conclusion, dexmedetomidine is a key component of contemporary anaesthetic and sedative procedures due to its wide range of therapeutic uses and safety record. To optimise its therapeutic potential while lowering hazards, more study is necessary, with a focus on long-term results and dosing strategy optimisation.

In conclusion dexmedetomidine can be considered effective in sedation, general and spinal anesthesia, and boosting the advantages in minimizing the necessities of anesthetic and opioid, stabilizing the hemodynamic and facilitating the outcomes of recovery. That is why its safety profile together with low levels of respiratory depression makes it useful in different clinical situations. Nonetheless, dose dependent side effects involving bradycardia and hypotension pose great importance in dose regulation and constant monitoring. The results presented in this study highlight the significance of dexmedetomidine as a key ingredient in modifying the patient care management in the course of the surgery with focusing on safety aspects.

1. Inagaki Y, Yamakage M, Sakamoto A, Okayama A, Oya N, Hiraoka T, Morita K. The Efficacy and Safety of Dexmedetomidine for Sedation During Surgery Under Epidural or Spinal Anesthesia: A Randomized, Double-Blind, Placebo-Controlled Study. Yonago Acta Med. 2022 Jan 4;65(1):14-25. doi: 10.33160/yam.2022.02.002. PMID: 35221757; PMCID: PMC8857668.
2. Bharthi Sekar E, Vijayaraghavan U, Sadiqbasha AM. Effect of Intravenous Dexmedetomidine on Spinal Anesthesia. Cureus. 2021 Jun 17;13(6): e15708. doi: 10.7759/cureus.15708. PMID: 34277292; PMCID: PMC8285763.
3. Tsung-Yu Hung, Ying-Chun Lin, Yeou-Lih Wang, Mei-Chi Lin, Efficacy and safety of intravenous dexmedetomidine as an adjuvant to general anesthesia in gynecological surgeries: A systematic review and meta-analysis of randomized controlled trials,Taiwanese Journal of Obsttrics and Gynecology,Volume 62, Issue 2,2023,Pages 239-251, ISSN 1028-4559,
4. Choudhary N, Patel A, Shah J, Efficacy of dexmedetomidine as intrathecal adjuvant in subarachnoid block and postoperative analgesia. Indian J Clin Anaesth 2017;4(2):219-224
5. Tsaousi GG, Pourzitaki C, Aloisio S, Bilotta F. Dexmedetomidine as a sedative and analgesic adjuvant in spine surgery: a systematic review and meta-analysis of randomized controlled trials. European journal of clinical pharmacology. 2018 Nov; 74:1377-89.
6. Liu X, Li Y, Kang L, Wang Q. Recent advances in the clinical value and potential of dexmedetomidine. Journal of Inflammation Research. 2021 Dec 30:7507-27.
7. Constantin JM, Momon A, Mantz J, Payen JF, De Jonghe B, Perbet S, Cayot S, Chanques G, Perreira B. Efficacy and safety of sedation with dexmedetomidine in critical care patients: a meta-analysis of randomized controlled trials. Anaesthesia Critical Care & Pain Medicine. 2016 Feb 1;35(1):7-15.
8. Abdel-Ghaffar HS, Mohamed SA, Fares KM, Osman MA. Safety and efficacy of dexmedetomidine in treating post spinal anesthesia shivering: a randomized clinically controlled dose-finding trial. Pain Physician. 2016;19(4):243.
9. Ter Bruggen FF, Eralp I, Jansen CK, Stronks DL, Huygen FJ. Efficacy of dexmedetomidine as a sole sedative agent in small diagnostic and therapeutic procedures: a systematic review. Pain Practice. 2017 Jul;17(6):829-40.
10. Obara S. Dexmedetomidine as an adjuvant during general anesthesia. Journal of anesthesia. 2018 Jun;32(3):313-5.
11. Kim H, Kim Y, Bae J, Yoo S, Lim YJ, Kim JT. Comparison of remimazolam and dexmedetomidine for intraoperative sedation in patients undergoing lower extremity surgery under spinal anesthesia: a randomized clinical trial. Regional Anesthesia & Pain Medicine. 2024 Feb 1;49(2):110-6.
12. Shen QH, Li HF, Zhou XY, Yuan XZ, Lu YP. Dexmedetomidine as an adjuvant for single spinal anesthesia in patients undergoing cesarean section: a system review and meta-analysis. Journal of International Medical Research. 2020 May;48(5):0300060520913423.
13. Weerink MA, Struys MM, Hannivoort LN, Barends CR, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clinical pharmacokinetics. 2017 Aug;56(8):893-913.
14. Inagaki Y, Yamakage M, Sakamoto A, Okayama A, Oya N, Hiraoka T, Morita K. The Efficacy and Safety of Dexmedetomidine for Sedation During Surgery Under Epidural or Spinal Anesthesia: A Randomized, Double-Blind, Placebo-Controlled Study. Yonago Acta Medica. 2022;65(1):14-25.
15. Lee S. Dexmedetomidine: present and future directions. Korean journal of anesthesiology. 2019 Aug 1;72(4):323-30.